Cargando…
Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer
To investigate the potential of sorafenib (SF) in preoperative chemotherapy for cervical cancer to reduce tumor volume, sorafenib micelles (SF micelles) with good stability and high drug loading were designed. SF micelles were prepared by film hydration followed by the ultrasonic method. The results...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705954/ https://www.ncbi.nlm.nih.gov/pubmed/34947619 http://dx.doi.org/10.3390/nano11123271 |
_version_ | 1784622073747865600 |
---|---|
author | Wang, Jun Lv, Fengmei Sun, Tao Zhao, Shoujin Chen, Haini Liu, Yu Liu, Zhepeng |
author_facet | Wang, Jun Lv, Fengmei Sun, Tao Zhao, Shoujin Chen, Haini Liu, Yu Liu, Zhepeng |
author_sort | Wang, Jun |
collection | PubMed |
description | To investigate the potential of sorafenib (SF) in preoperative chemotherapy for cervical cancer to reduce tumor volume, sorafenib micelles (SF micelles) with good stability and high drug loading were designed. SF micelles were prepared by film hydration followed by the ultrasonic method. The results showed that the SF micelles were spherical with an average particle size of 67.18 ± 0.66 nm (PDI 0.17 ± 0.01), a considerable drug loading of 15.9 ± 0.46% (w/w%) and satisfactory stability in buffers containing plasma or not for at least 2 days. In vitro release showed that SF was gradually released from SF micelles and almost completely released on the third day. The results of in vitro cellular intake, cytotoxicity and proliferation of cervical cancer cell TC-1 showed that SF micelles were superior to sorafenib (Free SF). For intravaginal administration, SF micelles were dispersed in HPMC (SF micelles/HPMC), showed good viscosity sustained-release profiles in vitro and exhibited extended residence in intravaginal in vivo. Compared with SF micelles dispersed in N.S. (SF micelles/N.S.), SF micelles/HPMC significantly reduced tumor size with a tumor weight inhibition rate of 73%. The results suggested that SF micelles had good potential for preoperative tumor shrinkage and improving the quality life of patients. |
format | Online Article Text |
id | pubmed-8705954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87059542021-12-25 Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer Wang, Jun Lv, Fengmei Sun, Tao Zhao, Shoujin Chen, Haini Liu, Yu Liu, Zhepeng Nanomaterials (Basel) Article To investigate the potential of sorafenib (SF) in preoperative chemotherapy for cervical cancer to reduce tumor volume, sorafenib micelles (SF micelles) with good stability and high drug loading were designed. SF micelles were prepared by film hydration followed by the ultrasonic method. The results showed that the SF micelles were spherical with an average particle size of 67.18 ± 0.66 nm (PDI 0.17 ± 0.01), a considerable drug loading of 15.9 ± 0.46% (w/w%) and satisfactory stability in buffers containing plasma or not for at least 2 days. In vitro release showed that SF was gradually released from SF micelles and almost completely released on the third day. The results of in vitro cellular intake, cytotoxicity and proliferation of cervical cancer cell TC-1 showed that SF micelles were superior to sorafenib (Free SF). For intravaginal administration, SF micelles were dispersed in HPMC (SF micelles/HPMC), showed good viscosity sustained-release profiles in vitro and exhibited extended residence in intravaginal in vivo. Compared with SF micelles dispersed in N.S. (SF micelles/N.S.), SF micelles/HPMC significantly reduced tumor size with a tumor weight inhibition rate of 73%. The results suggested that SF micelles had good potential for preoperative tumor shrinkage and improving the quality life of patients. MDPI 2021-12-01 /pmc/articles/PMC8705954/ /pubmed/34947619 http://dx.doi.org/10.3390/nano11123271 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Jun Lv, Fengmei Sun, Tao Zhao, Shoujin Chen, Haini Liu, Yu Liu, Zhepeng Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer |
title | Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer |
title_full | Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer |
title_fullStr | Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer |
title_full_unstemmed | Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer |
title_short | Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer |
title_sort | sorafenib nanomicelles effectively shrink tumors by vaginal administration for preoperative chemotherapy of cervical cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705954/ https://www.ncbi.nlm.nih.gov/pubmed/34947619 http://dx.doi.org/10.3390/nano11123271 |
work_keys_str_mv | AT wangjun sorafenibnanomicelleseffectivelyshrinktumorsbyvaginaladministrationforpreoperativechemotherapyofcervicalcancer AT lvfengmei sorafenibnanomicelleseffectivelyshrinktumorsbyvaginaladministrationforpreoperativechemotherapyofcervicalcancer AT suntao sorafenibnanomicelleseffectivelyshrinktumorsbyvaginaladministrationforpreoperativechemotherapyofcervicalcancer AT zhaoshoujin sorafenibnanomicelleseffectivelyshrinktumorsbyvaginaladministrationforpreoperativechemotherapyofcervicalcancer AT chenhaini sorafenibnanomicelleseffectivelyshrinktumorsbyvaginaladministrationforpreoperativechemotherapyofcervicalcancer AT liuyu sorafenibnanomicelleseffectivelyshrinktumorsbyvaginaladministrationforpreoperativechemotherapyofcervicalcancer AT liuzhepeng sorafenibnanomicelleseffectivelyshrinktumorsbyvaginaladministrationforpreoperativechemotherapyofcervicalcancer |